Electrophysiological Optimization of Left Ventricular Lead Placement in CRT
NCT ID: NCT02346097
Last Updated: 2018-06-18
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
122 participants
Study Classification
INTERVENTIONAL
Study Start Date
2015-02-16
Study Completion Date
2018-06-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to investigate if "optimal electrical resynchronization" achieved by targeting left ventricular lead placement to the myocardial region with the latest electrical activation combined with post-implant pacemakersettings for narrowing the paced QRS width causes an excess improvement in the pumping function of the heart (the left ventricular ejection fraction) in Cardiac Resynchronization Therapy (CRT)
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Empiric Versus Imaging Guided Left Ventricular Lead Placement in Cardiac Resynchronization Therapy
NCT01323686
Heart Failure
COMPLETED
NA
RESponders and QUadripolar LV Lead in CRT
NCT02433756
Heart Failure
UNKNOWN
DANISH-CRT - Does Electric Targeted LV Lead Positioning Improve Outcome in Patients With Heart Failure and Prolonged QRS
NCT03280862
Heart Failure
Branch Block, Bundle
ACTIVE_NOT_RECRUITING
NA
Acute Feedback on Left ventrIcular Lead Implantation Location for Cardiac Resynchronization Therapy
NCT01996397
Heart Failure
Resynchronization Therapy
Assessment of Acute CRT Response
COMPLETED
NA
Combining Myocardial Strain and Cardiac CT to Optimize Left Ventricular Lead Placement in CRT Treatment
NCT01426321
Heart Failure
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background:
Cardiac resynchronization therapy (CRT) is an established therapy in patients with a left ventricular (LV) ejection fraction (EF) \< 35 %, and an electrocardiogram (ECG) with prolonged QRS duration (1). The treatment is implemented by implanting a pacemaker with three pacing leads: One in the right atrium, one in the right ventricle (RV) and one in an epicardial vein through the coronary sinus, thereby establishing atrial-synchronized biventricular pacing to coordinate RV and LV contraction.
Despite the convincing effect of CRT on survival, symptoms, and LV function (2,3,4) as much as 30-40 % of the patients do not benefit clinically from the treatment, so-called non-responders (5,6). Annually around 600 CRT-systems are implanted in Denmark and about 3000 patients live with a CRT. The risk of complications associated with CRT-treatment is considerable (7), and a conservative estimate of the expenses for implanting a CRT-device is DKK 80.000. Consequently, the costs of CRT in non-responders are high, both for the patients and for the health economy.
Potential correctable reasons for non-response to CRT are non-optimal LV lead positioning and non-optimal pacemaker programming (5). At the Department of Cardiology, Aarhus University Hospital, Skejby, the clinical practice is to place the LV lead in the non-apical postero-lateral region aiming towards a myocardial segment with electrical activation occurring in the second half of the QRS complex in the surface ECG.
Retrospective studies have documented an improved response rate to CRT when the LV lead is placed in a myocardial region with late electrical activation and without scar tissue (8,9). Furthermore, lack of electrical resynchronization after CRT illustrated by unchanged or prolonged QRS duration is associated with poor clinical outcome (10) and programming the interventricular (VV) delay to obtain the narrowest QRS-complex has been suggested to increase CRT response rate (11,12).
A recent randomized controlled trial (ImagingCRT) conducted at our institution demonstrated that an imaging guided LV lead placement strategy targeting the latest mechanically activated myocardial segment (assessed by pre-implant echocardiography) and separate from scar tissue (determined by pre-implant myocardial scintigraphy) improves clinical response rate to CRT (data not yet published). This method has the potential to become routine clinical practice for LV lead placement at our institution.
Aim and hypothesis:
We aim to investigate if optimal electrical resynchronization achieved by targeting LV lead placement to the myocardial region with the latest electrical activation determined by systematic electrical mapping of all available epicardial veins combined with post-implant VV electrical optimization for narrowing the paced QRS width causes an excess improvement in LVEF after CRT.
We hypothesize that this will cause an excess increase in LVEF of 4 %, to an absolute increase in LVEF of 12 % as compared to an absolute increase in LVEF to 8 % using an imaging guided CRT-implantation strategy.
Methods:
All patients referred to CRT at Aarhus University Hospital, Skejby will be assessed for eligibility. Eligibility criteria and outcomes measures elsewhere at clinicaltrial.gov.
Study Course:
After written informed consent the patient will follow the study course as specified below.
The day before implantation of the CRT the following investigations are scheduled: Echocardiography (to asses LV function and dimensions), cardiac CT-scan (to localize all available epicardial veins), myocardial scintigraphy (82Rubidium positron emission tomography (Rb-PET)), to determine the extent and distribution of scar tissue and LVEF (13,14)), blood samples and clinical evaluation.
The patients are randomized to EITHER imgaging guided placement of the LV lead targeting the myocardial region with the latest mechanical activation and VV-interval settings programmed with simultaneous biventricular pacing (routine CRT-strategy arm) OR LV lead placement guided by procedural electrical mapping of all available cardiac veins targeting the myocardial region with the latest electrical activation combined with VV electrical optimization the day after implantation to achieve the narrowest paced QRS width (intervention arm).
The day after the implantation all patients undergo a high-pitch cardiac CT to verify LV lead position (15), pacemaker test, programming of VV-intervals and echocardiographic atrioventricular (AV) optimization.
One month after the implantation all patients have their pacemaker tested by a research nurse according to standard clinical practice.
Six months after CRT implantation the following investigations are repeated: Echocardiography, clinical evaluation, pacemaker test and blood samples. Rb-PET is also repeated to determine potential changes in myocardial perfusion and LVEF. Thereafter the patient will attend standard controls of the pacemaker every six month according to standard procedures.
Power Calculations and statistics:
We hypothesize that a CRT-strategy targeting optimal electrical resynchronization will result in an excess increase of 4 % in LVEF compared with the routine CRT-strategy, where an 8 % increase is expected. To identify this absolute increase in LVEF and to achieve a statistical power of 80 %, the study will need a sample size of 98 patients, given a standard deviation (SD) of 7 % in both groups, and a two-sided alpha value of 0.05. Furthermore, to achieve a statistical power of \> 80 % with a margen of noninferiority of 20 % for the secondary endpoint of clinical non-response to CRT (assuming a 75 % clinical response rate in the control group) we will need a sample size of 116 patients (given a two-sided alpha value of 0.05 %). Taking into consideration an expected loss of follow-up in approximately 5 % of the patients, we will include 122 patients.
All analyses will be conducted according to the intention-to-treat principle. Differences between groups will be tested using Students t-test, when normality is demonstrated; otherwise a non-parametric test (Mann-Whitney) is used. Categorical variables will be analyzed by χ2 test. A two-sided P- value of \<0.05 is considered significant.
Research Plan:
The Department of Cardiology, Aarhus University Hospital, have the capacity and equipment to conduct this trial. The group of investigators contributes with a deep and long-lasting experience in CRT-treatment and 150 de-novo CRT-devices are annually implanted at our institution. We plan to enroll the patients during a two and a half-year period. This study is planned to start in February 2015 as a PhD program for Charlotte Stephansen, MD. Charlotte Stephansen will be the prime investigator in charge of including the patients and she will perform all clinical evaluations and image acquisitions during the admission for CRT implantation and at the six month follow-up. She will also be in charge of analyzing data after study completion.
The results will be published in peer-reviewed international journals, and are expected to result in at least three papers. None of the investigators have any conflicts of interest to declare.
The study will be conducted according to the principles of the Helsinki Declaration II. The study will be approved by The Central Denmark Region Committees on Health Research Ethics, reported to the Danish Data Protection Agency, and registered on ClinicalTrials.gov.
Perspective:
No prospective randomized trials have previously investigated the effect of a CRT treatment-strategy targeting optimal electrical resynchronization achieved by guiding LV lead placement to the myocardial region with the latest electrical activation combined with post-implant VV electrical optimization for narrowing the paced QRS width.
It is expected that this method improves the response to CRT. The human and economic costs of CRT in non-responders are therefore expected to be reduced. If an excess increase in LVEF is achieved in this study, it will be possible to prevent and relieve invalidating symptoms and reduce mortality in selected heart failue patients in the future. The utility and potential benefits of participating in this study are expected to equalize the risks of exposure to ionizing radiation, possible side effects and inconvenience to the patient.
References:
Please refer to the reference chapter
Cardiac resynchronization therapy (CRT) is an established therapy in patients with a left ventricular (LV) ejection fraction (EF) \< 35 %, and an electrocardiogram (ECG) with prolonged QRS duration (1). The treatment is implemented by implanting a pacemaker with three pacing leads: One in the right atrium, one in the right ventricle (RV) and one in an epicardial vein through the coronary sinus, thereby establishing atrial-synchronized biventricular pacing to coordinate RV and LV contraction.
Despite the convincing effect of CRT on survival, symptoms, and LV function (2,3,4) as much as 30-40 % of the patients do not benefit clinically from the treatment, so-called non-responders (5,6). Annually around 600 CRT-systems are implanted in Denmark and about 3000 patients live with a CRT. The risk of complications associated with CRT-treatment is considerable (7), and a conservative estimate of the expenses for implanting a CRT-device is DKK 80.000. Consequently, the costs of CRT in non-responders are high, both for the patients and for the health economy.
Potential correctable reasons for non-response to CRT are non-optimal LV lead positioning and non-optimal pacemaker programming (5). At the Department of Cardiology, Aarhus University Hospital, Skejby, the clinical practice is to place the LV lead in the non-apical postero-lateral region aiming towards a myocardial segment with electrical activation occurring in the second half of the QRS complex in the surface ECG.
Retrospective studies have documented an improved response rate to CRT when the LV lead is placed in a myocardial region with late electrical activation and without scar tissue (8,9). Furthermore, lack of electrical resynchronization after CRT illustrated by unchanged or prolonged QRS duration is associated with poor clinical outcome (10) and programming the interventricular (VV) delay to obtain the narrowest QRS-complex has been suggested to increase CRT response rate (11,12).
A recent randomized controlled trial (ImagingCRT) conducted at our institution demonstrated that an imaging guided LV lead placement strategy targeting the latest mechanically activated myocardial segment (assessed by pre-implant echocardiography) and separate from scar tissue (determined by pre-implant myocardial scintigraphy) improves clinical response rate to CRT (data not yet published). This method has the potential to become routine clinical practice for LV lead placement at our institution.
Aim and hypothesis:
We aim to investigate if optimal electrical resynchronization achieved by targeting LV lead placement to the myocardial region with the latest electrical activation determined by systematic electrical mapping of all available epicardial veins combined with post-implant VV electrical optimization for narrowing the paced QRS width causes an excess improvement in LVEF after CRT.
We hypothesize that this will cause an excess increase in LVEF of 4 %, to an absolute increase in LVEF of 12 % as compared to an absolute increase in LVEF to 8 % using an imaging guided CRT-implantation strategy.
Methods:
All patients referred to CRT at Aarhus University Hospital, Skejby will be assessed for eligibility. Eligibility criteria and outcomes measures elsewhere at clinicaltrial.gov.
Study Course:
After written informed consent the patient will follow the study course as specified below.
The day before implantation of the CRT the following investigations are scheduled: Echocardiography (to asses LV function and dimensions), cardiac CT-scan (to localize all available epicardial veins), myocardial scintigraphy (82Rubidium positron emission tomography (Rb-PET)), to determine the extent and distribution of scar tissue and LVEF (13,14)), blood samples and clinical evaluation.
The patients are randomized to EITHER imgaging guided placement of the LV lead targeting the myocardial region with the latest mechanical activation and VV-interval settings programmed with simultaneous biventricular pacing (routine CRT-strategy arm) OR LV lead placement guided by procedural electrical mapping of all available cardiac veins targeting the myocardial region with the latest electrical activation combined with VV electrical optimization the day after implantation to achieve the narrowest paced QRS width (intervention arm).
The day after the implantation all patients undergo a high-pitch cardiac CT to verify LV lead position (15), pacemaker test, programming of VV-intervals and echocardiographic atrioventricular (AV) optimization.
One month after the implantation all patients have their pacemaker tested by a research nurse according to standard clinical practice.
Six months after CRT implantation the following investigations are repeated: Echocardiography, clinical evaluation, pacemaker test and blood samples. Rb-PET is also repeated to determine potential changes in myocardial perfusion and LVEF. Thereafter the patient will attend standard controls of the pacemaker every six month according to standard procedures.
Power Calculations and statistics:
We hypothesize that a CRT-strategy targeting optimal electrical resynchronization will result in an excess increase of 4 % in LVEF compared with the routine CRT-strategy, where an 8 % increase is expected. To identify this absolute increase in LVEF and to achieve a statistical power of 80 %, the study will need a sample size of 98 patients, given a standard deviation (SD) of 7 % in both groups, and a two-sided alpha value of 0.05. Furthermore, to achieve a statistical power of \> 80 % with a margen of noninferiority of 20 % for the secondary endpoint of clinical non-response to CRT (assuming a 75 % clinical response rate in the control group) we will need a sample size of 116 patients (given a two-sided alpha value of 0.05 %). Taking into consideration an expected loss of follow-up in approximately 5 % of the patients, we will include 122 patients.
All analyses will be conducted according to the intention-to-treat principle. Differences between groups will be tested using Students t-test, when normality is demonstrated; otherwise a non-parametric test (Mann-Whitney) is used. Categorical variables will be analyzed by χ2 test. A two-sided P- value of \<0.05 is considered significant.
Research Plan:
The Department of Cardiology, Aarhus University Hospital, have the capacity and equipment to conduct this trial. The group of investigators contributes with a deep and long-lasting experience in CRT-treatment and 150 de-novo CRT-devices are annually implanted at our institution. We plan to enroll the patients during a two and a half-year period. This study is planned to start in February 2015 as a PhD program for Charlotte Stephansen, MD. Charlotte Stephansen will be the prime investigator in charge of including the patients and she will perform all clinical evaluations and image acquisitions during the admission for CRT implantation and at the six month follow-up. She will also be in charge of analyzing data after study completion.
The results will be published in peer-reviewed international journals, and are expected to result in at least three papers. None of the investigators have any conflicts of interest to declare.
The study will be conducted according to the principles of the Helsinki Declaration II. The study will be approved by The Central Denmark Region Committees on Health Research Ethics, reported to the Danish Data Protection Agency, and registered on ClinicalTrials.gov.
Perspective:
No prospective randomized trials have previously investigated the effect of a CRT treatment-strategy targeting optimal electrical resynchronization achieved by guiding LV lead placement to the myocardial region with the latest electrical activation combined with post-implant VV electrical optimization for narrowing the paced QRS width.
It is expected that this method improves the response to CRT. The human and economic costs of CRT in non-responders are therefore expected to be reduced. If an excess increase in LVEF is achieved in this study, it will be possible to prevent and relieve invalidating symptoms and reduce mortality in selected heart failue patients in the future. The utility and potential benefits of participating in this study are expected to equalize the risks of exposure to ionizing radiation, possible side effects and inconvenience to the patient.
References:
Please refer to the reference chapter
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Congestive Heart Failure
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Optimal electrical resynchronization
Cardiac Resynchronization Therapy: LV lead implant according to electrical activation mapping of available epicardial veins to identify the latest electrical activated myocardial region. Post-implant interventricular (VV) electrical optimization for narrowing the paced QRS width. Post-implant standard pacemaker settings: Atrioventricular (AV) interval 100-130 ms and VV interval settings with simultaneous biventricular pacing.
Day 1 after implantation: ECG, AV-optimization guided by echocardiography, high-pitch cardiac CT to verify LV lead position.
Programming of the VV interval to obtain the narrowest QRS-width
Group Type
EXPERIMENTAL
Cardiac Resynchronization Therapy (St. Jude Qaudripolar LV lead)
Intervention Type
DEVICE
Optimal electrical resynchronization vs. routine CRT strategy, imaging guided. For more details refer to ""Arm descriptions"
Routine CRT-strategy, imaging guided
Cardiac Resynchronization Therapy: LV lead implant guided by echocardiography and Rb-PET towards the latest mechanically activated myocardial segment and separate from scar. Post-implant VV electrical optimization for narrowing the paced QRS width. Standard pacemaker settings for both groups: AV-interval 100-130 ms and VV-interval settings with simultaneous biventricular pacing.
Day 1 after implantation: ECG, AV-optimization guided by echocardiography, high-pitch cardiac CT to verify LV lead position.
Continue standard interventricular pacing interval settings with simultaneous pacing in both ventricular leads.
Group Type
ACTIVE_COMPARATOR
Cardiac Resynchronization Therapy (St. Jude Qaudripolar LV lead)
Intervention Type
DEVICE
Optimal electrical resynchronization vs. routine CRT strategy, imaging guided. For more details refer to ""Arm descriptions"
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cardiac Resynchronization Therapy (St. Jude Qaudripolar LV lead)
Optimal electrical resynchronization vs. routine CRT strategy, imaging guided. For more details refer to ""Arm descriptions"
Intervention Type
DEVICE
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
St. Jude Qaudripolar LV lead
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Symptomatic heart failure (New York Heart Association (NYHA) functional class II - IV) despite optimal medical therapy
* ECG with left bundle branch block and QRS ≥ 120 ms
* LVEF ≤ 35 %
* Age \> 40 years
* Written informed consent Patients with an indwelling single- or dual chamber pacemaker and a paced QRS \> 180 ms are eligible for enrollment.
* ECG with left bundle branch block and QRS ≥ 120 ms
* LVEF ≤ 35 %
* Age \> 40 years
* Written informed consent Patients with an indwelling single- or dual chamber pacemaker and a paced QRS \> 180 ms are eligible for enrollment.
Exclusion Criteria
* Expected lifetime \< 6 months
* Expected heart-surgery within the next 6 months
* Recent (\< 3 months) myocardial infarction or coronary artery bypass graft (CABG)
* Pregnant or lactating
* No written informed consent Cardiac CT will not be performed in patients where this is contraindicated, i.e. in the presence of depressed renal function (estimated Glomerular Filtration Rate (eGFR) \< 30 ml (milliters)/minute), thyrotoxicosis or in the case of former serious reactions to the contrast media.
* Expected heart-surgery within the next 6 months
* Recent (\< 3 months) myocardial infarction or coronary artery bypass graft (CABG)
* Pregnant or lactating
* No written informed consent Cardiac CT will not be performed in patients where this is contraindicated, i.e. in the presence of depressed renal function (estimated Glomerular Filtration Rate (eGFR) \< 30 ml (milliters)/minute), thyrotoxicosis or in the case of former serious reactions to the contrast media.
Minimum Eligible Age
40 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aarhus University Hospital
OTHER
Sponsor Role
collaborator
University of Aarhus
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jens Cosedis Nielsen, Professor
Role: STUDY_DIRECTOR
Aarhus University Hospital, Sekjby, Department of Cardiology
Mads Brix Kronborg, MD, PhD
Role: STUDY_DIRECTOR
Aarhus University Hospital, Sekjby, Department of Cardiology
Anders Sommer Knudsen, MD
Role: STUDY_DIRECTOR
Aarhus University Hospital, Sekjby, Department of Cardiology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aarhus University Hospital, Skejby, Department of Cardiology
Aarhus, , Denmark
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Denmark
References
Explore related publications, articles, or registry entries linked to this study.
European Society of Cardiology (ESC); European Heart Rhythm Association (EHRA); Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA, Cleland J, Deharo JC, Delgado V, Elliott PM, Gorenek B, Israel CW, Leclercq C, Linde C, Mont L, Padeletti L, Sutton R, Vardas PE. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace. 2013 Aug;15(8):1070-118. doi: 10.1093/europace/eut206. Epub 2013 Jun 24. No abstract available.
Reference Type
BACKGROUND
Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ, Packer M, Clavell AL, Hayes DL, Ellestad M, Trupp RJ, Underwood J, Pickering F, Truex C, McAtee P, Messenger J; MIRACLE Study Group. Multicenter InSync Randomized Clinical Evaluation. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002 Jun 13;346(24):1845-53. doi: 10.1056/NEJMoa013168.
Reference Type
BACKGROUND
Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004 May 20;350(21):2140-50. doi: 10.1056/NEJMoa032423.
Reference Type
BACKGROUND
Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005 Apr 14;352(15):1539-49. doi: 10.1056/NEJMoa050496. Epub 2005 Mar 7.
Reference Type
BACKGROUND
Yu CM, Sanderson JE, Gorcsan J 3rd. Echocardiography, dyssynchrony, and the response to cardiac resynchronization therapy. Eur Heart J. 2010 Oct;31(19):2326-37. doi: 10.1093/eurheartj/ehq263. Epub 2010 Aug 13.
Reference Type
BACKGROUND
Kronborg MB, Mortensen PT, Kirkfeldt RE, Nielsen JC. Very long term follow-up of cardiac resynchronization therapy: clinical outcome and predictors of mortality. Eur J Heart Fail. 2008 Aug;10(8):796-801. doi: 10.1016/j.ejheart.2008.06.013. Epub 2008 Jul 10.
Reference Type
BACKGROUND
Kirkfeldt RE, Johansen JB, Nohr EA, Jorgensen OD, Nielsen JC. Complications after cardiac implantable electronic device implantations: an analysis of a complete, nationwide cohort in Denmark. Eur Heart J. 2014 May;35(18):1186-94. doi: 10.1093/eurheartj/eht511. Epub 2013 Dec 17.
Reference Type
BACKGROUND
Gold MR, Birgersdotter-Green U, Singh JP, Ellenbogen KA, Yu Y, Meyer TE, Seth M, Tchou PJ. The relationship between ventricular electrical delay and left ventricular remodelling with cardiac resynchronization therapy. Eur Heart J. 2011 Oct;32(20):2516-24. doi: 10.1093/eurheartj/ehr329. Epub 2011 Aug 29.
Reference Type
BACKGROUND
Kandala J, Upadhyay GA, Altman RK, Parks KA, Orencole M, Mela T, Kevin Heist E, Singh JP. QRS morphology, left ventricular lead location, and clinical outcome in patients receiving cardiac resynchronization therapy. Eur Heart J. 2013 Aug;34(29):2252-62. doi: 10.1093/eurheartj/eht123. Epub 2013 Apr 9.
Reference Type
BACKGROUND
Kronborg MB, Nielsen JC, Mortensen PT. Electrocardiographic patterns and long-term clinical outcome in cardiac resynchronization therapy. Europace. 2010 Feb;12(2):216-22. doi: 10.1093/europace/eup364. Epub 2009 Nov 14.
Reference Type
BACKGROUND
Tamborero D, Vidal B, Tolosana JM, Sitges M, Berruezo A, Silva E, Castel M, Matas M, Arbelo E, Rios J, Villacastin J, Brugada J, Mont L. Electrocardiographic versus echocardiographic optimization of the interventricular pacing delay in patients undergoing cardiac resynchronization therapy. J Cardiovasc Electrophysiol. 2011 Oct;22(10):1129-34. doi: 10.1111/j.1540-8167.2011.02085.x. Epub 2011 Jun 2.
Reference Type
BACKGROUND
Tamborero D, Mont L, Sitges M, Silva E, Berruezo A, Vidal B, Delgado V, Tolosana JM, Godoy M, Castel A, Brugada J. Optimization of the interventricular delay in cardiac resynchronization therapy using the QRS width. Am J Cardiol. 2009 Nov 15;104(10):1407-12. doi: 10.1016/j.amjcard.2009.07.006.
Reference Type
BACKGROUND
Ypenburg C, Schalij MJ, Bleeker GB, Steendijk P, Boersma E, Dibbets-Schneider P, Stokkel MP, van der Wall EE, Bax JJ. Impact of viability and scar tissue on response to cardiac resynchronization therapy in ischaemic heart failure patients. Eur Heart J. 2007 Jan;28(1):33-41. doi: 10.1093/eurheartj/ehl379. Epub 2006 Nov 22.
Reference Type
BACKGROUND
Bravo PE, Chien D, Javadi M, Merrill J, Bengel FM. Reference ranges for LVEF and LV volumes from electrocardiographically gated 82Rb cardiac PET/CT using commercially available software. J Nucl Med. 2010 Jun;51(6):898-905. doi: 10.2967/jnumed.109.073858. Epub 2010 May 19.
Reference Type
BACKGROUND
Sommer A, Kronborg MB, Norgaard BL, Gerdes C, Mortensen PT, Nielsen JC. Left and right ventricular lead positions are imprecisely determined by fluoroscopy in cardiac resynchronization therapy: a comparison with cardiac computed tomography. Europace. 2014 Sep;16(9):1334-41. doi: 10.1093/europace/euu056. Epub 2014 Mar 30.
Reference Type
BACKGROUND
Stephansen C, Sommer A, Kronborg MB, Jensen JM, Bouchelouche K, Nielsen JC. Electrically guided versus imaging-guided implant of the left ventricular lead in cardiac resynchronization therapy: a study protocol for a double-blinded randomized controlled clinical trial (ElectroCRT). Trials. 2018 Nov 1;19(1):600. doi: 10.1186/s13063-018-2930-y.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Electro-1-CRT
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Stimulus Intensity in Left Ventricular Leads
NCT01060449
COMPLETED
NA
Cardiac Resynchronization Therapy (CRT) and Left Ventricular Assist Devices (LVAD) Therapy
NCT02083419
COMPLETED
A Pilot Study of Interventricular Septal Puncture for Cardiac Resynchronization Therapy to Treat Heart Failure
NCT01818765
COMPLETED
NA
Effect of Targeting Left Ventricular Lead Position on the Rate of Response to Cardiac Resynchronization Therapy.
NCT00399594
COMPLETED
PHASE2/PHASE3
A Comparison of Two Techniques for Choosing the Best Place to Put a Pacing Lead for Cardiac Resynchronisation Therapy
NCT02061241
COMPLETED
Acute Optimization of Cardiac Resynchronization Therapy (CRT)Using Echocardiography and SonR
NCT01293526
WITHDRAWN
NA
Optimizing CRT With ECGI
NCT03492788
TERMINATED
NA
HEAL-HF: A Cardiac Resynchronization Therapy (CRT) Outcomes Study
NCT00370526
TERMINATED
PHASE4
ConTempoRary Cardiac Stimulation in Clinical practicE: lEft, BivEntriculAr, Right, and conDuction System Pacing
NCT06324682
RECRUITING
Optimal Left Ventricular Lead Positioning During Cardiac Resynchronisation Therapy; Comparison of Two Methods of Targeting
NCT03769272
UNKNOWN
Targeted Left Ventricular Lead Placement, Comparison of Active Fixation Bipolar and Passive Quadripolar Pacemaker Leads
NCT04632472
COMPLETED
NA
Correlating QLV Interval to Left Ventricular (LV) Lead Position in Patients Receiving Cardiac Resynchronization Therapy.
NCT02166762
COMPLETED
NA
Comparison of Epicardial Versus Conventional Lead Placement in Cardiac Resynchronization Therapy
NCT01302470
COMPLETED
NA
Cardiac Resynchronization Therapy (CRT) Based Heart Failure Monitoring Study
NCT00632372
COMPLETED
LV Endocardial Cardiac Resynchronisation Therapy
NCT02174289
UNKNOWN
NA
Evaluation of Left Ventricular (LV) Lead Positioning Using MediGuide
NCT01917266
COMPLETED
Optimization of Cardiac Resynchronization Therapy by Non-Invasive Imaging of Cardiac Electrophysiology
NCT04662970
RECRUITING
NA
Quadripolar CRT-D On Currently Approved Lead SystemS
NCT02232984
COMPLETED
Multi-lead ECG to Effectively Optimize Resynchronization Devices: New CRT Recipients
NCT04083690
UNKNOWN
NA
Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure
NCT07069738
RECRUITING
NA
Safety and Performance of Electrodes Implanted in the Left Ventricle
NCT01905670
COMPLETED
NA
Heart Failure Study of Multi-site Pacing Effects on Ventriculoarterial Coupling
NCT03189368
COMPLETED
Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT)
NCT00683696
TERMINATED
PHASE2/PHASE3
Triple-site Biventricular Stimulation in the Optimization of CRT
NCT02350842
COMPLETED
NA
Resynchronization/Defibrillation for Ambulatory Heart Failure Trial
NCT00251251
COMPLETED
NA